Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
AssigneesJanssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
InventorsDan Barouch, Macaya Julie Douoguih, Gaston Rafael Picchio
Life of this patent
Estimating the term…
Abstract
Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.
Claims6
A method for generating an immune response against a Zika virus in a human subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising adenoviral vectors of the Ad26 serotype comprising a nucleic acid sequence encoding a Zika virus antigen, wherein the Zika virus antigen comprises the amino acid sequence of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein about 5×1010 adenoviral vectors to about 1×1011 adenoviral vectors are administered per dose to the subject in need thereof, and wherein the pharmaceutical composition is administered in two doses to the human subject in a prime-boost regimen.
Dependencies are inferred from the claim text.